Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Nab-paclitaxel + Pembrolizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Nab-paclitaxel | Abraxane | ABI-007|Paclitaxel Protein-bound | Chemotherapy - Taxane 2 | Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary). |
Pembrolizumab | Keytruda | MK-3475 | Immune Checkpoint Inhibitor 151 PD-L1/PD-1 antibody 98 | Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous squamous cell carcinoma, MSI-H or dMMR or TMB high advanced solid tumors, NSCLC and CD274 (PD-L1)-expressing NSCLC, gastric and GEJ adenocarcinoma, squamous esophageal carcinoma, cervical cancer, and triple-negative breast cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, with axitinib or lenvatinib in RCC, with Lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, in combination with platinum and fluoropyrimidine-based chemotherapy for patients with esophageal or gastroesophageal carcinoma, in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma, and in combination with platinum-based chemotherapy, with or without bevacizumab, for patients with CD274 (PD-L1)-expressing (CPS>=1) cervical cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | triple-receptor negative breast cancer | sensitive | Nab-paclitaxel + Pembrolizumab | Guideline | Actionable | Combination of Keytruda (pembrolizumab) and Abraxane (nab-paclitaxel) is included in guidelines for patients with recurrent or metastatic CD274 (PD-L1)-positive (CPS >or= 10) triple-receptor negative breast cancer (NCCN.org). | detail... |
CD274 positive | lung adenocarcinoma | predicted - sensitive | Nab-paclitaxel + Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, a lung adenocarcinoma patient with CD274 (PD-L1) expression of 30% and harboring CD74-ROS1 and ROS1 G2032K demonstrated a partial response after being treated with the combination therapy of Keytruda (pembrolizumab) and Abraxane (nab-paclitaxel) for two cycles (PMID: 32208297). | 32208297 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02752685 | Phase II | Nab-paclitaxel + Pembrolizumab | Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT03240016 | Phase II | Nab-paclitaxel + Pembrolizumab | Abraxane With Anti-PD1/PDL1 in Cisplatin-ineligible Patients With Advanced Urothelial Cancer | Active, not recruiting | USA | 0 |
NCT02733250 | Phase Ib/II | Nab-paclitaxel + Pembrolizumab | Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001) | Completed | CAN | 0 |
NCT05382286 | Phase III | Pembrolizumab + Sacituzumab govitecan-hziy Carboplatin + Gemcitabine + Pembrolizumab Paclitaxel + Pembrolizumab Nab-paclitaxel + Pembrolizumab | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04) | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | AUT | 12 |
NCT05233696 | Phase II | Nab-paclitaxel + Pembrolizumab Paclitaxel + Pembrolizumab | Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC | Withdrawn | USA | 0 |
NCT04297605 | Phase I | Pembrolizumab + Pemetrexed Disodium Nab-paclitaxel + Pembrolizumab | Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 | Recruiting | USA | 0 |
NCT04964960 | Phase II | Paclitaxel + Pembrolizumab Nab-paclitaxel + Pembrolizumab Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab | Pembro+Chemo in Brain Mets | Recruiting | USA | 0 |
NCT04895358 | Phase III | Nab-paclitaxel Nab-paclitaxel + Pembrolizumab Capecitabine + Pembrolizumab Paclitaxel + Pembrolizumab Capecitabine Daunoxome + Pembrolizumab Daunoxome Paclitaxel | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | AUT | 20 |